
Deirdra R Terrell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7561260/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Advances, 2022, 6, 664-671.	2.5	53
2	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances, 2022, 6, 4915-4923.	2.5	42
3	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789.	0.6	4
4	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 2022, 6, 4975-4982.	2.5	21
5	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances, 2021, 5, 3951-3959.	2.5	49
6	Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Lithuania), 2020, 56, 667.	0.8	20
7	A user guide to the American Society of Hematology clinical practice guidelines. Blood Advances, 2020, 4, 2095-2110.	2.5	14
8	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at Enrolment until 2017. Hamostaseologie, 2020, 40, .	0.9	0
9	Thrombotic thrombocytopenic purpura patients' attitudes toward depression management: A qualitative study. Health Science Reports, 2019, 2, e136.	0.6	6
10	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	1.7	99
11	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	2.5	684
12	Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy. American Journal of Hematology, 2019, 94, E8-E11.	2.0	17
13	Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study. Blood, 2019, 134, 931-931.	0.6	2
14	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist–oncologists. Journal of Thrombosis and Thrombolysis, 2018, 46, 24-30.	1.0	11
15	Platelet Counts during Pregnancy. New England Journal of Medicine, 2018, 379, 32-43.	13.9	157
16	Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients. Blood, 2018, 132, 376-376.	0.6	1
17	Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion, 2017, 57, 2532-2538.	0.8	18
18	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600.	2.5	207

#	Article	IF	CITATIONS
19	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178.	0.6	68
20	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Annals of Hematology, 2016, 95, 1077-1087.	0.8	43
21	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094.	0.6	99
22	Depression in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2016, 91, E462-3.	2.0	8
23	Longâ€ŧerm outcomes of healthâ€related quality of life following diverse thrombotic microangiopathy syndromes. American Journal of Hematology, 2016, 91, E278-9.	2.0	1
24	Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, 709-714.	2.0	59
25	Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125, 616-618.	0.6	282
26	<scp>D</scp> rugâ€induced thrombotic microangiopathy: <scp>E</scp> xperience of the <scp>O</scp> klahoma registry and the BloodCenter of <scp>W</scp> isconsin. American Journal of Hematology, 2015, 90, 406-410.	2.0	95
27	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	1.1	4
28	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. American Journal of the Medical Sciences, 2014, 347, 190-194.	0.4	13
29	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680.	0.6	61
30	Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion, 2014, 54, 3257-3259.	0.8	16
31	Thrombotic Thrombocytopenic Purpura (TTP) Patient Attitudes Regarding Depression Management: a Qualitative Study. Blood, 2014, 124, 203-203.	0.6	1
32	Drug-induced thrombocytopenia in children. Pediatric Blood and Cancer, 2013, 60, 1975-1981.	0.8	21
33	First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?. Transfusion, 2013, 53, 235-237.	0.8	24
34	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	0.8	193
35	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029.	0.6	161
36	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	1.7	69

#	Article	IF	CITATIONS
37	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188.	0.8	35
38	Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. American Journal of Hematology, 2012, 87, 843-847.	2.0	11
39	Prevalence of primary immune thrombocytopenia in Oklahoma. American Journal of Hematology, 2012, 87, 848-852.	2.0	75
40	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532.	0.8	63
41	Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Transfusion, 2012, 52, 1614-1621.	0.8	6
42	A case report of long-term complete remission following cessation of romiplostim dosing in a previously severe ITP patient Journal of Clinical Oncology, 2012, 30, e17001-e17001.	0.8	0
43	Incidence, Age, and Gender of Children with Thrombotic Thrombocytopenic Purpura (TTP) Associated with Severe, Acquired ADAMTS13 Deficiency Blood, 2012, 120, 2196-2196.	0.6	1
44	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. Blood, 2012, 120, 1094-1094.	0.6	0
45	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243.	0.8	27
46	Fatigue in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 2011, 86, 420-429.	1.1	74
47	Systemic infections mimicking thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 743-751.	2.0	87
48	Quinine-Induced Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Characteristic Clinical Presentation and High Risk for Chronic Kidney Disease (CKD). Blood, 2011, 118, 2216-2216.	0.6	0
49	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	0.6	477
50	Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages*. European Journal of Haematology, 2010, 84, 421-429.	1.1	46
51	The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. American Journal of Hematology, 2010, 85, 174-180.	2.0	308
52	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847.	2.0	75
53	Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. Thrombosis and Haemostasis, 2010, 103, 1203-1209.	1.8	11
54	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura Blood, 2010, 116, 3694-3694.	0.6	0

4

#	Article	IF	CITATIONS
55	Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137.	2.9	48
56	Corticosteroid sideâ€effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. European Journal of Haematology, 2009, 83, 175-182.	1.1	64
57	Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. European Journal of Haematology, 2009, 83, 497-498.	1.1	11
58	Successful treatment of cyclic thrombocytopenia with thrombopoietinâ€mimetic agents: A report of two patients. American Journal of Hematology, 2009, 84, 459-461.	2.0	10
59	Longâ€ŧerm deficits in healthâ€ŧelated quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 118-124.	0.8	61
60	Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion, 2009, 49, 392-394.	0.8	42
61	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887.	0.8	99
62	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101.	0.8	73
63	Referral of patients with thrombocytopenia from primary care clinicians to hematologists. Blood, 2009, 113, 4126-4127.	0.6	8
64	Twiceâ€daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion, 2008, 48, 349-357.	0.8	38
65	Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpuraâ€Hemolytic Uremic Syndrome Registry. Journal of Clinical Apheresis, 2008, 23, 129-137.	0.7	38
66	Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2008, 23, 168-169.	0.7	12
67	Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707.	1.2	50
68	The Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286.	1.1	40
69	Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica, 2008, 93, 1445-1449.	1.7	20
70	The Prevalence of Immune Thrombocytopenic Purpura (ITP) Blood, 2008, 112, 1277-1277.	0.6	3
71	What Level of Platelet Count and Symptoms Trigger Referral of Patients with Thrombocytopenia from Primary Care Physicians to Hematologists?. Blood, 2008, 112, 4692-4692.	0.6	0
72	Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP). Blood, 2008, 112, 4707-4707.	0.6	1

#	Article	IF	CITATIONS
73	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases. Oncologist, 2007, 12, 11-19.	1.9	117
74	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) Blood, 2007, 110, 1311-1311.	0.6	3
75	The Frequency of Rheumatic Disease Autoantibodies in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) Blood, 2007, 110, 2090-2090.	0.6	1
76	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS Blood, 2007, 110, 1317-1317.	0.6	2
77	Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Frequency, Presenting Features, and Clinical Outcomes Blood, 2007, 110, 1315-1315.	0.6	2
78	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT) Blood, 2007, 110, 1302-1302.	0.6	0
79	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community service. Journal - Oklahoma State Medical Association, 2007, 100, 273-8.	0.4	8
80	Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2006, 46, 154-156.	0.8	131
81	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2006, 108, 1067-1067.	0.6	3
82	Long-Term Abnormalities of Patient-Reported Outcomes after Recovery from Thrombotic Thrombocytopenic Purpura (TTP) Using Health Related Quality-of-Life (QOL) Measurements Blood, 2006, 108, 458-458.	0.6	2
83	Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2006, 108, 91-91.	0.6	4
84	Detecting Drugs That Cause Thrombocytopenia: A Comparison of Published Case Reports and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database Blood, 2006, 108, 462-462.	0.6	0
85	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases Blood, 2006, 108, 1062-1062.	0.6	Ο
86	Is immune thrombocytopenic purpura less common among black Americans?. Blood, 2005, 105, 1368-1369.	0.6	13
87	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion, 2004, 44, 294-304.	0.8	219
88	Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2004, 44, 1149-1158.	0.8	124
89	The Oklahoma thrombotic thrombocytopenic Purpura-Hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Seminars in Hematology, 2004, 41, 60-67.	1.8	125
90	Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 2004, 104, 2623-2634.	0.6	561

#	Article	IF	CITATIONS
91	Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy. Annals of Internal Medicine, 2004, 140, 112.	2.0	114
92	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities Blood, 2004, 104, 856-856.	0.6	2
93	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency Blood, 2004, 104, 857-857.	0.6	11
94	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes Blood, 2004, 104, 858-858.	0.6	3
95	A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study Group. Journal of Clinical Apheresis, 2003, 18, 16-20.	0.7	28
96	Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. American Journal of Hematology, 2003, 73, 135-140.	2.0	47
97	Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion, 2003, 43, 415-416.	0.8	69
98	Quinine Allergy Causing Acute Severe Systemic Illness: Report of 4 Patients Manifesting Multiple Hematologic, Renal, and Hepatic Abnormalities. Baylor University Medical Center Proceedings, 2003, 16, 21-26.	0.2	16